{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:57Z","timestamp":1790960577116,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,25]]},"DOI":"10.7759\/cureus.77949","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T08:35:51Z","timestamp":1737794151000},"source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Safety of Vancomycin, Linezolid, and Ceftaroline in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA): A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ibrahim M","family":"Dighriri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"AlMutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J","family":"Alhusayni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah M","family":"Balharith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A","family":"Aljuwaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailah K","family":"Alfayez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadi M","family":"Althubaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada A","family":"Alosaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama W","family":"Jameel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asalah M","family":"Alansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner NA","year":"2019","unstructured":"Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al.. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol. 2019, 17:203-18. 10.1038\/s41579-018-0147-4","journal-title":"Nat Rev Microbiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong SY","year":"2015","unstructured":"Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015, 28:603-61. 10.1128\/CMR.00134-14","journal-title":"Clin Microbiol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122108599","article-title":"The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA)","volume":"99","author":"Enright MC","year":"2002","unstructured":"Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A. 2002, 99:7687-92. 10.1073\/pnas.122108599","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1067284","article-title":"MRSA compendium of epidemiology, transmission, pathophysiology, treatment, and prevention within one health framework","volume":"13","author":"Shoaib M","year":"2022","unstructured":"Shoaib M, Aqib AI, Muzammil I, et al.. MRSA compendium of epidemiology, transmission, pathophysiology, treatment, and prevention within one health framework. Front Microbiol. 2022, 13:1067284. 10.3389\/fmicb.2022.1067284","journal-title":"Front Microbiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections - United States","volume":"68","author":"Kourtis AP","year":"2019","unstructured":"Kourtis AP, Hatfield K, Baggs J, et al.. Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections - United States. MMWR Morb Mortal Wkly Rep. 2019, 68:214-19. 10.15585\/mmwr.mm6809e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref6","unstructured":"WHO bacterial priority pathogens list, 2024. bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. (2024). Accessed: October 16, 2024: https:\/\/www.who.int\/publications\/i\/item\/9789240093461."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01162.x","article-title":"Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy","volume":"11 Suppl 4","author":"Cunha BA","year":"2005","unstructured":"Cunha BA. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect. 2005, 11 Suppl 4:33-42. 10.1111\/j.1469-0691.2005.01162.x","journal-title":"Clin Microbiol Infect"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.GPP3-0057-2018","article-title":"Antibiotic resistance and the MRSA problem","volume":"7","author":"Vestergaard M","year":"2019","unstructured":"Vestergaard M, Frees D, Ingmer H. Antibiotic resistance and the MRSA problem. Microbiol Spectr. 2019, 7:2. 10.1128\/microbiolspec.GPP3-0057-2018","journal-title":"Microbiol Spectr"},{"key":"ref9","article-title":"Vancomycin resistance in Staphylococcus aureus","volume":"90","author":"McGuinness WA","year":"2017","unstructured":"McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017, 90:269-81.","journal-title":"Yale J Biol Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01344.x","article-title":"The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus","volume":"12 Suppl 1","author":"Appelbaum PC","year":"2006","unstructured":"Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006, 12 Suppl 1:16-23. 10.1111\/j.1469-0691.2006.01344.x","journal-title":"Clin Microbiol Infect"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00203-023-03699-2","article-title":"A review of current antibiotic resistance and promising antibiotics with novel modes of action to combat antibiotic resistance","volume":"205","author":"Chen L","year":"2023","unstructured":"Chen L, Kumar S, Wu H. A review of current antibiotic resistance and promising antibiotics with novel modes of action to combat antibiotic resistance. Arch Microbiol. 2023, 205:356. 10.1007\/s00203-023-03699-2","journal-title":"Arch Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus","volume":"69","author":"Zhanel GG","year":"2009","unstructured":"Zhanel GG, Sniezek G, Schweizer F, et al.. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 2009, 69:809-31. 10.2165\/00003495-200969070-00003","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian SM","year":"2018","unstructured":"Hashemian SM, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018, 12:1759-67. 10.2147\/DDDT.S164515","journal-title":"Drug Des Devel Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13090866","article-title":"Efficacy and safety of antibiotics in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections: a systematic review and network meta-analysis","volume":"13","author":"Liu Q","year":"2024","unstructured":"Liu Q, He D, Wang L, et al.. Efficacy and safety of antibiotics in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections: a systematic review and network meta-analysis. Antibiotics (Basel). 2024, 13:866. 10.3390\/antibiotics13090866","journal-title":"Antibiotics (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review","volume":"4","author":"Cosimi RA","year":"2017","unstructured":"Cosimi RA, Beik N, Kubiak DW, Johnson JA. Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review. Open Forum Infect Dis. 2017, 4:ofx084. 10.1093\/ofid\/ofx084","journal-title":"Open Forum Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783x-15-12-507","article-title":"Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - comparison of pharmacology and clinical efficacy","volume":"15","author":"Pletz MW","year":"2010","unstructured":"Pletz MW, Burkhardt O, Welte T. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - comparison of pharmacology and clinical efficacy. Eur J Med Res. 2010, 15:507-13. 10.1186\/2047-783x-15-12-507","journal-title":"Eur J Med Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm369","article-title":"Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan","volume":"60","author":"Kohno S","year":"2007","unstructured":"Kohno S, Yamaguchi K, Aikawa N, et al.. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother. 2007, 60:1361-9. 10.1093\/jac\/dkm369","journal-title":"J Antimicrob Chemother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0518-2","article-title":"Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia","volume":"8","author":"Zhang Y","year":"2019","unstructured":"Zhang Y, Wang Y, Van Driel ML, et al.. Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia. Antimicrob Resist Infect Control. 2019, 8:72. 10.1186\/s13756-019-0518-2","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown NM","year":"2021","unstructured":"Brown NM, Goodman AL, Horner C, Jenkins A, Brown EM. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC Antimicrob Resist. 2021, 3:dlaa114. 10.1093\/jacamr\/dlaa114","journal-title":"JAC Antimicrob Resist"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s42269-023-01072-3","article-title":"Methicillin-resistant Staphylococcus aureus: novel treatment approach breakthroughs","volume":"47","author":"Maddiboyina B","year":"2023","unstructured":"Maddiboyina B, Roy H, Ramaiah M, Sarvesh CN, Kosuru SH, Nakkala RK, Nayak BS. Methicillin-resistant Staphylococcus aureus: novel treatment approach breakthroughs. Bull Natl Res Cent. 2023, 47:95. 10.1186\/s42269-023-01072-3","journal-title":"Bull Natl Res Cent"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey GR","year":"2010","unstructured":"Corey GR, Wilcox M, Talbot GH, et al.. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010, 51:641-50. 10.1086\/655827","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein E","year":"2001","unstructured":"Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001, 32:402-12. 10.1086\/318486","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink RG","year":"2012","unstructured":"Wunderink RG, Niederman MS, Kollef MH, et al.. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012, 54:621-9. 10.1093\/cid\/cir895","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1771","article-title":"Comparison of linezolid and vancomycin for methicillin-resistant Staphylococcus aureus pneumonia: institutional implications","volume":"36","author":"Tong MC","year":"2016","unstructured":"Tong MC, Wisniewski CS, Wolf B, Bosso JA. Comparison of linezolid and vancomycin for methicillin-resistant Staphylococcus aureus pneumonia: institutional implications. Pharmacotherapy. 2016, 36:731-9. 10.1002\/phar.1771","journal-title":"Pharmacotherapy"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0011","article-title":"Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus","volume":"134","author":"Wunderink RG","year":"2008","unstructured":"Wunderink RG, Mendelson MH, Somero MS, et al.. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest. 2008, 134:1200-7. 10.1378\/chest.08-0011","journal-title":"Chest"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2013.09.011","article-title":"The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia","volume":"43","author":"Chavanet P","year":"2013","unstructured":"Chavanet P. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. Med Mal Infect. 2013, 43:451-5. 10.1016\/j.medmal.2013.09.011","journal-title":"Med Mal Infect"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Dennis LS","year":"2002","unstructured":"Dennis LS, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002, 34:1481-90. 10.1086\/340353","journal-title":"Clin Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study","volume":"67","author":"O'Riordan W","year":"2018","unstructured":"O'Riordan W, McManus A, Teras J, et al.. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018, 67:657-66. 10.1093\/cid\/ciy165","journal-title":"Clin Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00712-12","article-title":"TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections","volume":"56","author":"Stryjewski ME","year":"2012","unstructured":"Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, Corey GR. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012, 56:5476-83. 10.1128\/AAC.00712-12","journal-title":"Antimicrob Agents Chemother"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study","volume":"72","author":"Pullman J","year":"2017","unstructured":"Pullman J, Gardovskis J, Farley B, et al.. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017, 72:3471-80. 10.1093\/jac\/dkx329","journal-title":"J Antimicrob Chemother"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET)","volume":"73","author":"Overcash JS","year":"2021","unstructured":"Overcash JS, Kim C, Keech R, et al.. Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET). Clin Infect Dis. 2021, 73:e1507-17. 10.1093\/cid\/ciaa974","journal-title":"Clin Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn372","article-title":"Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates","volume":"62","author":"Rehm SJ","year":"2008","unstructured":"Rehm SJ, Boucher H, Levine D, et al.. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother. 2008, 62:1413-21. 10.1093\/jac\/dkn372","journal-title":"J Antimicrob Chemother"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens","volume":"52","author":"Rubinstein E","year":"2011","unstructured":"Rubinstein E, Lalani T, Corey GR, et al.. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011, 52:31-40. 10.1093\/cid\/ciq031","journal-title":"Clin Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-012-0501-9","article-title":"Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections","volume":"19","author":"Aikawa N","year":"2013","unstructured":"Aikawa N, Kusachi S, Mikamo H, et al.. Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J Infect Chemother. 2013, 19:447-55. 10.1007\/s10156-012-0501-9","journal-title":"J Infect Chemother"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.06.018","article-title":"Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis","volume":"34","author":"Itani KM","year":"2012","unstructured":"Itani KM, Biswas P, Reisman A, Bhattacharyya H, Baruch AM. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis. Clin Ther. 2012, 34:1667-73.e1. 10.1016\/j.clinthera.2012.06.018","journal-title":"Clin Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1261-9","article-title":"An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection","volume":"15","author":"Kauf TL","year":"2015","unstructured":"Kauf TL, McKinnon P, Corey GR, et al.. An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. BMC Infect Dis. 2015, 15:503. 10.1186\/s12879-015-1261-9","journal-title":"BMC Infect Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/s0012-3692(15)33412-7","article-title":"Linezolid vs vancomycin*: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink RG","year":"2003","unstructured":"Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin*: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003, 124:1789-97. 10.1016\/s0012-3692(15)33412-7","journal-title":"Chest"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1825","article-title":"The modified APACHE II score outperforms Curb65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia","volume":"133","author":"Kollef KE","year":"2008","unstructured":"Kollef KE, Reichley RM, Micek ST, Kollef MH. The modified APACHE II score outperforms Curb65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest. 2008, 133:363-9. 10.1378\/chest.07-1825","journal-title":"Chest"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1177\/0885066610392893","article-title":"Clinical outcomes of linezolid vs vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia: retrospective analysis","volume":"26","author":"Chan JD","year":"2011","unstructured":"Chan JD, Pham TN, Wong J, Hessel M, Cuschieri J, Neff M, Dellit TH. Clinical outcomes of linezolid vs vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia: retrospective analysis. J Intensive Care Med. 2011, 26:385-91. 10.1177\/0885066610392893","journal-title":"J Intensive Care Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2012.10.011","article-title":"Improved outcome of ventilator-associated pneumonia caused by methicillin-resistant Staphylococcus aureus in a trauma population","volume":"205","author":"Gonzalez RP","year":"2013","unstructured":"Gonzalez RP, Rostas J, Simmons JD, Allen J, Frotan MA, Brevard SB. Improved outcome of ventilator-associated pneumonia caused by methicillin-resistant Staphylococcus aureus in a trauma population. Am J Surg. 2013, 205:255-8; discussion 258. 10.1016\/j.amjsurg.2012.10.011","journal-title":"Am J Surg"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1390","article-title":"Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia","volume":"34","author":"Caffrey AR","year":"2014","unstructured":"Caffrey AR, Morrill HJ, Puzniak LA, Laplante KL. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy. 2014, 34:473-80. 10.1002\/phar.1390","journal-title":"Pharmacotherapy"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/cc13914","article-title":"Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study","volume":"18","author":"Peyrani P","year":"2014","unstructured":"Peyrani P, Wiemken TL, Kelley R, et al.. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care. 2014, 18:R118. 10.1186\/cc13914","journal-title":"Crit Care"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2016.10.058","article-title":"Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: a retrospective cohort analysis: effectiveness of linezolid in the elderly","volume":"35","author":"Takada H","year":"2017","unstructured":"Takada H, Hifumi T, Nishimoto N, et al.. Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: a retrospective cohort analysis: effectiveness of linezolid in the elderly. Am J Emerg Med. 2017, 35:245-8. 10.1016\/j.ajem.2016.10.058","journal-title":"Am J Emerg Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"Kato H","year":"2021","unstructured":"Kato H, Hagihara M, Asai N, Shibata Y, Koizumi Y, Yamagishi Y, Mikamo H. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2021, 24:98-105. 10.1016\/j.jgar.2020.12.009","journal-title":"J Glob Antimicrob Resist"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu C","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al.. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011, 52:285-92. 10.1093\/cid\/cir034","journal-title":"Clin Infect Dis"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1396-1","article-title":"Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia","volume":"8","author":"Reveles KR","year":"2015","unstructured":"Reveles KR, Mortensen EM, Attridge RT, Frei CR. Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia. BMC Res Notes. 2015, 8:450. 10.1186\/s13104-015-1396-1","journal-title":"BMC Res Notes"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00456-0","article-title":"Comparative efficacy and safety of vancomycin, linezolid, tedizolid, and daptomycin in treating patients with suspected or proven complicated skin and soft tissue infections: an updated network meta-analysis","volume":"10","author":"Feng J","year":"2021","unstructured":"Feng J, Xiang F, Cheng J, Gou Y, Li J. Comparative efficacy and safety of vancomycin, linezolid, tedizolid, and daptomycin in treating patients with suspected or proven complicated skin and soft tissue infections: an updated network meta-analysis. Infect Dis Ther. 2021, 10:1531-47. 10.1007\/s40121-021-00456-0","journal-title":"Infect Dis Ther"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00663-3","article-title":"Linezolid vs vancomycin in induced thrombocytopenia","volume":"11","author":"Al-Harbi D","year":"2022","unstructured":"Al-Harbi D, Alturaiki A, Alshngeetee A, et al.. Linezolid vs vancomycin in induced thrombocytopenia. Infect Dis Ther. 2022, 11:1649-60. 10.1007\/s40121-022-00663-3","journal-title":"Infect Dis Ther"},{"key":"ref49","article-title":"Linezolid","author":"Azzouz A","year":"2024","unstructured":"Azzouz A, Preuss CV. Linezolid. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/334836-efficacy-and-safety-of-vancomycin-linezolid-and-ceftaroline-in-the-treatment-of-methicillin-resistant-staphylococcus-aureus-mrsa-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T08:35:54Z","timestamp":1737794154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/334836-efficacy-and-safety-of-vancomycin-linezolid-and-ceftaroline-in-the-treatment-of-methicillin-resistant-staphylococcus-aureus-mrsa-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.77949","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,25]]}}}